pertaining to the continuance and improvement of functions within the authority of the Department of Health and Human Services concerning protections for human subjects in research.

SACHRP is authorized to have 11 public voting members. The members are selected from among individuals possessing demonstrated experience and expertise in any of the several disciplines and fields pertinent to human subjects protection and/or clinical research. The Committee's public members are appointed by the Secretary. All public members of the Committee are classified as special government employees (SGEs). The Committee structure includes nonvoting *ex-officio* representation from eight Departmental agencies.

On September 12, 2024 the Secretary approved for the SACHRP charter to be renewed. The new charter will be effected and filed with the appropriate Congressional committees and the Library of Congress on or about October 1, 2024. Renewal of the Committee's charter gives authorization for the Committee to continue to operate until October 1, 2026.

A copy of the SACHRP charter is available on the Committee's website at *https://www.hhs.gov/ohrp/sachrpcommittee/charter/index.html.* A copy of the charter can also be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is *www.facadatabase.gov.*

Julie Kaneshiro,

Acting Director, Office for Human Research Protections.

[FR Doc. 2024–22797 Filed 10–2–24; 8:45 am] BILLING CODE 4150–36–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; Aging Primate.

Date: November 18, 2024.

Time: 1:00 p.m. to 5:30 p.m. *Agenda:* To review and evaluate grant applications.

Place: National Institute on Aging, 5601 Fishers Lane, Rockville, MD 20892, (Virtual Meeting).

Contact Person: Dario Dieguez, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20814, (301) 827–3101, *dario.dieguez@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: September 30, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–22876 Filed 10–2–24; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a hybrid (virtual/inperson) meeting on November 12, 2024. The topic for this meeting will be "Opportunities for Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research." The meeting is open to the public. **DATES:** The meeting will be held on November 12, 2024, from 8:30 a.m. to 5:00 p.m. EDT.

ADDRESSES: This hybrid meeting will convene virtually via the Zoom online video conferencing platform or in person at: National Institutes of Health Campus, Natcher Conference Center (Building 45), Room E1/E2, 45 Center Drive, Bethesda, MD 20894. Attendance for the meeting will be accessible to members of the public who register at *www.scgcorp.com/DMICC2024/ Registration* by November 5, 2024.

FOR FURTHER INFORMATION CONTACT: For further information concerning this meeting, including a draft agenda, which will be posted when available,

see the DMICC website, https:// www.niddk.nih.gov/about-niddk/ advisory-coordinating-committees/ diabetes-mellitus-interagencycoordinating-committeedmicc?dkrd=lgdmn0022, or contact Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, Bethesda, MD 20892, telephone: 301– 435–1011; email: dmicc@mail.nih.gov.

SUPPLEMENTARY INFORMATION: Inaccordance with 42 U.S.C. 285c-3, the DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and comprising members of the Department of Health and Human Services and other federal agencies that support diabetesrelated activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The November 12, 2024 DMICC meeting will focus on "Opportunities for Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research.'

Any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, there will not be time on the agenda for oral comments from members of the public.

Members of the public who would like to receive email notification about future DMICC meetings should register for the listserv available on the DMICC website, https://www.niddk.nih.gov/ about-niddk/advisory-coordinatingcommittees/diabetes-mellitusinteragency-coordinating-committeedmicc?dkrd=lgdmn0022.

Dated: September 24, 2024.

William T. Cefalu,

Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

[FR Doc. 2024–22863 Filed 10–2–24; 8:45 am]

BILLING CODE 4140-01-P